ORCID Profile
0000-0002-1074-7699
Current Organisation
University of Southampton
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Public Library of Science (PLoS)
Date: 21-06-2016
Publisher: Springer Science and Business Media LLC
Date: 2013
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 02-2015
Publisher: Public Library of Science (PLoS)
Date: 15-10-2013
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 19-06-2013
Publisher: Oxford University Press (OUP)
Date: 12-2012
DOI: 10.1093/IJE/DYS210
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 11-2010
Publisher: American Thoracic Society
Date: 10-2017
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 02-01-2014
Publisher: Informa UK Limited
Date: 23-01-2013
Publisher: Elsevier BV
Date: 12-2014
Publisher: Springer Science and Business Media LLC
Date: 06-11-2013
Abstract: Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially in settings where anaemia is common. Eligible HIV-infected pregnant women in Burkina Faso, Kenya and South Africa were followed from 28 weeks of pregnancy until 12–24 months after delivery (n = 1070). Women with a CD4 count of 200-500cells/mm 3 and gestational age 28–36 weeks were randomly assigned to zidovudine-containing triple-ARV prophylaxis continued during breastfeeding up to 6-months, or to zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour. Additionally, two cohorts were established, women with CD4 counts: cells/mm 3 initiated antiretroviral therapy, and cells/mm 3 received zidovudine during pregnancy plus sd-NVP at labour. Mild (haemoglobin 8.0-10.9 g/dl) and severe anaemia (haemoglobin 8.0 g/dl) occurrence were assessed across study arms, using Kaplan-Meier and multivariable Cox proportional hazards models. At enrolment (corresponded to a median 32 weeks gestation), median haemoglobin was 10.3 g/dl (IQR = 9.2-11.1). Severe anaemia occurred subsequently in 194 (18.1%) women, mostly in those with low baseline haemoglobin, lowest socio-economic category, advanced HIV disease, prolonged breastfeeding (≥6 months) and shorter ARV exposure. Severe anaemia incidence was similar in the randomized arms (equivalence P -value = 0.32). After 1–2 months of ARV’s, severe anaemia was significantly reduced in all groups, though remained highest in the low CD4 cohort. Severe anaemia occurs at a similar rate in women receiving longer triple zidovudine-containing regimens or shorter prophylaxis. Pregnant women with pre-existing anaemia and advanced HIV disease require close monitoring. ISRCTN71468401
Publisher: Oxford University Press (OUP)
Date: 09-05-2012
DOI: 10.1093/CID/CIS461
Publisher: Springer Science and Business Media LLC
Date: 02-04-2012
Publisher: Public Library of Science (PLoS)
Date: 27-08-2019
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 2004
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Marie-Louise Newell.